TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer

Gaweł-Bęben, K., Ali, N., Ellis, V., Velasco, G., Poghosyan, Z., Ager, Ann ORCID: https://orcid.org/0000-0002-5763-8908 and Knauper, Vera ORCID: https://orcid.org/0000-0002-3965-9924 2018. TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer. Cell Biology International 42 (3) , pp. 273-280. 10.1002/cbin.10832

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (893kB) | Preview

Abstract

TMEFF2 is a type I transmembrane protein with two follistatin (FS) and one EGF-like domain over-expressed in prostate cancer, however its biological role in prostate cancer development and progression remains unclear, which may, at least in part, be explained by its proteolytic processing. The extracellular part of TMEFF2 (TMEFF2-ECD) is cleaved by ADAM17 and the membrane-retained fragment is further processed by the gamma-secretase complex. TMEFF2 shedding is increased with cell crowding, a condition associated with the tumour microenvironment, which was mediated by oxidative stress signalling, requiring jun-kinase (JNK) activation. Moreover, we have identified that TMEFF2 is also a novel substrate for other proteases implicated in prostate cancer, including two ADAMs (ADAM9 and ADAM12) and the type II transmembrane serine proteinases (TTSPs) matriptase-1 and hepsin. Whereas cleavage by ADAM9 and ADAM12 generates previously identified TMEFF2-ECD, proteolytic processing by matriptase-1 and hepsin produced TMEFF2 fragments, composed of TMEFF2-ECD or FS and/or EGF-like domains as well as novel membrane retained fragments. Differential TMEFF2 processing from a single transmembrane protein may be a general mechanism to modulate transmembrane protein levels and domains, dependent on the repertoire of ADAMs or TTSPs expressed by the target cell.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Dentistry Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Wiley-Blackwell
ISSN:	1065-6995
Date of First Compliant Deposit:	10 August 2017
Date of Acceptance:	26 July 2017
Last Modified:	05 May 2023 09:02
URI:	https://orca.cardiff.ac.uk/id/eprint/103493

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item